Breaking

China tells EU it can’t accept Russia losing its war against Ukraine, official says
Trump expects Hamas response to ceasefire in hours as new details emerge on proposal
C-Level Survey: IoT Dominates Tech Roadmaps in Key Industrial Sectors
CoTec Holdings Corp. Announces Second Closing of Life Offering and Concurrent Private Placement
Hempalta Secures 90-Day FCC Forbearance Extension as Company Completes Certification of 2024 Carbon Credits
Elephant kills two female tourists from the UK and New Zealand in Zambian national park
What is happening in South Korea? Seoul has caught the lovebug that nobody wants
Russia launches record number of drones at Ukraine after latest Trump-Putin phone call

Facebook
Twitter
Google Plus
Instagram
Pinterest
Vimeo

Investing
Stock
Latest News
Editor’s Pick
Economy
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

By December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Hempalta Secures 90-Day FCC Forbearance Extension as Company Completes Certification of 2024 Carbon Credits

CoTec Holdings Corp. Announces Second Closing of Life Offering and Concurrent Private Placement

Bert Dohmen: Gold, Silver Key as Stock Market Bull Trap Looms

Enter Your Information Below To Receive Latest News, And Articles.
Your name

Your email
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest Posts
Categories
- Economy (906)
- Editor's Pick (485)
- Investing (3,479)
- Latest News (3,492)
- Stock (1,161)
About Rightinvestingway

Disclaimer: Rightinvestingway.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 Rightinvestingway.com

Top

Type above and press Enter to search. Press Esc to cancel.